Flume Health
We're Hiring!
Flume Health Company Growth, Stability & Outlook
What People Are Saying About Flume Health
-
Investor Backing & Capital Strength: Feedback suggests a $30M Series A in 2022 led by Optum Ventures with participation from Cigna Ventures provides meaningful runway for execution. This capital underpins the pivot and subsequent product buildout.
-
Future-Ready Strategy: After divesting its TPA unit in October 2023, the company refocused on a healthcare data/AI platform (Relay) with enterprise-grade controls (SOC 2 Type II, HIPAA alignment, HITRUST), targeting payer/TPA needs. This sharpened software focus typically supports more scalable, higher‑margin growth.
-
Product Line Growth: The launch of the Relay integration platform (March 2023) and expanded modules/use cases on the site/docs indicate continued product development. Recent case studies and content, alongside selective hiring, suggest active build-and-sell motion.
